Sanegene Bio and Huadong Medicine Announce Strategic Collaboration to Co-Develop siRNA Therapeutics for Chronic Metabolic Diseases

On November 9, 2023, SANEGENEBIO (hereinafter referred to as "SANEGENEBIO"), and Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine", SZ.000963), a wholly-owned subsidiary of Huadong Medicine, reached a strategic cooperation. Both parties will jointly develop siRNA drugs for chronic metabolic diseases based on SANEGENEBIO's LEAD™ (Ligand and Enhancer Assisted Delivery) innovative technology platform, and further explore cooperation opportunities to develop novel siRNA drugs in other therapeutic fields.

This collaboration will fully leverage Huadong Medicine's deep expertise in pharmaceutical development and extensive experience in drug clinical trials and commercialization, effectively utilizing SANEGENEBIO's proprietary small nucleic acid drug LEAD™ (Ligand and Enhancer Assisted Delivery) development platform and advanced technology to accelerate the progress of providing breakthrough innovative treatment solutions for patients with chronic metabolic diseases.

As a novel category of drugs, small nucleic acid drugs differ from traditional small molecules and antibody drugs, which regulate at the protein level. Instead, they target an upstream process by modulating gene and protein expression through a wider range of RNA targets. These drugs boast multiple advantages, including abundant potential targets, broad indications, strong targeting specificity, long-lasting effects, and excellent safety. In recent years, they have demonstrated significant therapeutic potential not only in rare diseases but also across various chronic disease fields. In response to substantial unmet clinical needs, the two parties will join hands to leverage their complementary strengths, accelerating the development of siRNA drugs for numerous disease areas, thus providing more patients with newer and better treatment options.

Dr. Wang Weimin, founder and CEO of SANEGENEBIO, said:

"We are delighted to collaborate with Huadong Medicine and leverage our proprietary novel small nucleic acid drug LEAD™ platform technology to advance drug development. Huadong Medicine has deep expertise and extensive presence in the field of metabolic disease treatment. This collaboration will combine the strengths of both parties in their respective domains, enabling us to fully unlock the application potential of RNAi technology. We look forward to working with Huadong Medicine to drive the development of new siRNA drugs, addressing unmet clinical needs in the chronic metabolic disease market and benefiting patients worldwide as soon as possible."

Dr. Liu Dongzhou, Chief Scientific Officer of Huadong Medicine, stated:

"SANEGENEBIO is dedicated to developing novel nucleic acid drugs based on RNA interference (RNAi) technology, which aligns perfectly with Huadong Medicine's vision for growth in the nucleic acid drug field. SANEGENEBIO owns a proprietary technology platform for novel nucleic acid drug research and development. Huadong Medicine will leverage its strengths in research, registration, and commercialization within the metabolic field to collaborate closely with SANEGENEBIO, jointly advancing the development of novel siRNA drugs. Together, they aim to bring better and safer next-generation treatments to patients with chronic metabolic diseases."

About Huadong Medicine

Huadong Medicine Co., Ltd. (SZ.000963) was founded in 1993, with its headquarters located in Hangzhou, Zhejiang. The company adheres to the corporate philosophy of "research-based and patient-centered." After more than 20 years of development, the company's business covers the entire pharmaceutical industry chain, encompassing four major business segments: pharmaceuticals manufacturing, pharmaceuticals commerce, medical aesthetics, and industrial microbiology. It has grown into a large comprehensive pharmaceutical listed company that integrates pharmaceutical research and development, production, and distribution. In 2022, the company achieved revenue of 37.715 billion yuan, with over 10,000 employees, possessing extensive commercial coverage and marketing capabilities. For more information, please visit www.eastchinapharm.com.

About SANEGENEBIO

SANEGENEBIO was founded in early 2021 as a biopharmaceutical company dedicated to developing novel small nucleic acid drugs based on RNA interference (RNAi) technology, with research and development centers in both China and the United States. The founding team is a renowned group of experts in the field of nucleic acid drugs, possessing years of experience in nucleic drug development and cutting-edge technical expertise in the industry. Over the past two years, the company has established a globally leading nucleic acid drug platform with proprietary intellectual property, featuring chemical modification and delivery technologies for both intrahepatic and extrahepatic applications, enabling more efficient knockdown of disease-causing genes. SANEGENEBIO has rapidly advanced the research and development of a series of small nucleic acid products covering cardiovascular and metabolic diseases, immune-related diseases, and neurological disorders. SANEGENEBIO is committed to scientific innovation, creating novel RNAi therapeutics to address unmet global medical needs and benefit patients and their families. For more information, please visit the SANEGENEBIO official website at www.sanegenebio.com.

Editor: Baiji

Disclaimer: The views expressed in this article are solely those of the author and do not represent the position of PharmEasy. We welcome exchanges and additional insights in the comment section; for reprints, please be sure to credit the author and source. If there are any issues regarding the content, copyright, or other aspects of the work, please leave a message on this platform, and we will address it promptly.